[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][=N][C][=Branch2][Ring2][O][=N][C][=C][Ring1][=Branch1][O][C][C@][Branch2][Ring1][Branch1][C][C@H1][Ring1][Ring1][C][=Branch1][C][=O][N][C][=N][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][F][C][=C][C][=Branch1][=Branch1][=C][C][=C][Ring1][=Branch1][F][C]"}, {"from": "gpt", "value": "The molecule is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to \"switch on\" sleep-related circuits, but rather an inability to \"switch-off\" wake-promoting circuits. Whereas historically popular pharmacologic treatments for insomnia (e.g. [zopiclone], [zolpidem], benzodiazepines) focus on enhancing sleep drive via modulation of GABA and melatonin receptors, lemborexant and other orexin antagonists (e.g. [suvorexant]) act to counteract inappropriate wakefulness. This novel mechanism of action offers potential advantages over classic hypnotic agents, including a more favorable adverse effect profile and potentially greater efficacy, and may signal the beginning of a new wave of treatment options for patients suffering from insomnia."}]